MARLBOROUGH, Mass. and NEW ORLEANS, March 28, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that the CHAMPION-AF global clinical trial met all primary and secondary ...
Please provide your email address to receive an email when new articles are posted on . OPTION is a head-to-head trial of left atrial appendage closure with Watchman FLX vs. anticoagulation after ...
CAMBRIA COUNTY, Pa (WJAC) — Conemaugh Memorial Medical Center reached a significant milestone this week by successfully performing their 300th procedure with the "watchman" device. The "watchman left ...
For patients with non-valvular atrial fibrillation (AFib) who had no contraindications to taking oral anticoagulants, the use of a device to close off the left atrial appendage in the heart—a small ...
TCT 489: The Comparison of Tissue Characteristics of Restenosis After Coronary Interventions: Insights From a Histological Analysis After Directional Coronary Atherectomy Receive the the latest news, ...
Please provide your email address to receive an email when new articles are posted on . In patients with atrial fibrillation, left atrial appendage closure was superior to anticoagulation for bleeding ...
In late April 2026, Boston Scientific reported quarterly revenue of US$5.20 billion, up 11.6% year on year and ahead of ...
CHICAGO -- For patients at high risk of stroke who underwent catheter-based atrial fibrillation ablation, left atrial appendage closure led to less bleeding compared with oral anticoagulation, the ...
Medicare typically covers Watchman surgery under Part A (hospital insurance) if deemed medically necessary for reducing stroke risk in patients with non-valvular atrial fibrillation. Coverage often ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results